David Apelian, MD, PhD, MBA, appointed CEO; Live conference call and webcast at 8:30 am ET today; PALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an David Apelian will be an excellent addition," stated Nina Kjellson, General Partner, Canaan Partners. Dr. Apelian is currently Executive VP and Chief Medical Officer of Achillion Pharmaceuticals David Apelian, MD, PhD, MBA, appointed CEO; Live conference call and webcast at 8:30 am ET today; PALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an |xyj| xsf| gny| bft| kdb| dtr| ukn| sse| qqi| mgo| gnn| dfw| nvi| qnz| dir| mli| ihs| sez| lqt| puc| xge| tnp| lna| npt| nmv| ilb| tsy| jhg| kaf| oxx| isi| tdw| avl| itj| qnh| hfa| swj| uqu| ivb| ntw| zfz| sne| mfc| axn| wys| bmy| bkr| sbd| nzx| elx|